Samuel Backenroth, CFO, Treasurer & Secretary at NeuBase Therapeutics, Inc. (NBSE), bought 1,000 shares at $6.00 ($6K) on 2020-04-30, disclosed to the SEC on 2020-05-04.
Open-market purchase of $6k NBSE by CFO, Treasurer & Secretary. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| OHRP | BUY | 2016-05-24 | $8K | — | Filing → |
| OHRP | BUY | 2015-02-10 | $10K | — | Filing → |